Please provide your email address to receive an email when new articles are posted on . Patients who achieved enthesitis resolution were more likely to have improvements in pain and physical function.
The monoclonal antibody guselkumab (Tremfya), which targets the p19 subunit of interleukin (IL)-23, was effective for treating the enthesitis and dactylitis components of psoriatic arthritis (PsA), ...
Please provide your email address to receive an email when new articles are posted on . Dactylitis indicates a more severe disease phenotype independently linked to increased disease burden, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results